ifosfamide has been researched along with Lymphoma, T Cell, Peripheral in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL." | 1.72 | Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma. ( Gentille, C; Joshi, J; Pingali, SR; Randhawa, J; Sarfraz, H; Shah, S, 2022) |
| "Lenalidomide treatment demonstrated for the first time in the literature impressive and long-term clinical efficacy in a heavily pretreated chemorefractory AITL patient." | 1.39 | Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up. ( Bocchia, M; Cencini, E; Defina, M; Fabbri, A; Fontanelli, G; Gozzetti, A; Mazzei, MA; Pietrini, A; Volterrani, L, 2013) |
| "Except for a temporal exacerbation of bronchiolitis obliterans organizing pneumonia, she has been free from disease for more than a year without other treatments against lymphoma." | 1.34 | Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. ( Chiba, S; Izutsu, K; Kako, S; Kanda, Y; Kurokawa, M; Motokura, T; Oshima, K; Sato, H, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gentille, C | 1 |
| Sarfraz, H | 1 |
| Joshi, J | 1 |
| Randhawa, J | 1 |
| Shah, S | 1 |
| Pingali, SR | 1 |
| Shafagati, N | 1 |
| Koh, MJ | 1 |
| Boussi, L | 1 |
| Park, HJ | 1 |
| Stuver, R | 1 |
| Bain, P | 1 |
| Foss, FM | 1 |
| Shen, C | 1 |
| Jain, S | 1 |
| Nagahama, J | 1 |
| Nishikawa, T | 1 |
| Tasaki, T | 1 |
| Yasudome, Y | 1 |
| Nakamura, T | 1 |
| Abematsu, T | 1 |
| Nakagawa, S | 1 |
| Kodama, Y | 1 |
| Tanimoto, A | 1 |
| Okamoto, Y | 1 |
| Van de Wyngaert, Z | 1 |
| Coppo, P | 1 |
| Cervera, P | 1 |
| Fabiani, B | 1 |
| Lemonnier, MP | 1 |
| Corre, E | 1 |
| Marjanovic, Z | 1 |
| Aoudjhane, M | 1 |
| Mohty, M | 1 |
| Duléry, R | 1 |
| Wedekind, MF | 1 |
| Saraf, A | 1 |
| Willen, F | 1 |
| Audino, AN | 1 |
| Strati, P | 1 |
| Chihara, D | 1 |
| Oki, Y | 1 |
| Fayad, LE | 1 |
| Fowler, N | 1 |
| Nastoupil, L | 1 |
| Romaguera, JE | 1 |
| Samaniego, F | 1 |
| Garg, N | 1 |
| Feng, L | 1 |
| Wesson, ET | 1 |
| Ruben, CE | 1 |
| Stafford, MD | 1 |
| Nieto, Y | 1 |
| Khouri, IF | 1 |
| Hosing, C | 1 |
| Horowitz, SB | 1 |
| Kamble, RT | 1 |
| Fanale, MA | 1 |
| Mikesch, JH | 1 |
| Kuhlmann, M | 1 |
| Demant, A | 1 |
| Krug, U | 1 |
| Thoennissen, GB | 1 |
| Schmidt, E | 1 |
| Kessler, T | 1 |
| Schliemann, C | 1 |
| Pohlen, M | 1 |
| Mohr, M | 1 |
| Evers, G | 1 |
| Köhler, G | 1 |
| Wessling, J | 1 |
| Mesters, R | 1 |
| Müller-Tidow, C | 1 |
| Berdel, WE | 1 |
| Thoennissen, NH | 1 |
| Salamoon, M | 1 |
| Bachour, M | 1 |
| Hussein, T | 1 |
| Kenj, M | 1 |
| Sieniawski, M | 1 |
| Angamuthu, N | 1 |
| Boyd, K | 1 |
| Chasty, R | 1 |
| Davies, J | 1 |
| Forsyth, P | 1 |
| Jack, F | 1 |
| Lyons, S | 1 |
| Mounter, P | 1 |
| Revell, P | 1 |
| Proctor, SJ | 1 |
| Lennard, AL | 1 |
| Simon, A | 1 |
| Peoch, M | 1 |
| Casassus, P | 1 |
| Deconinck, E | 1 |
| Colombat, P | 1 |
| Desablens, B | 1 |
| Tournilhac, O | 1 |
| Eghbali, H | 1 |
| Foussard, C | 1 |
| Jaubert, J | 1 |
| Vilque, JP | 1 |
| Rossi, JF | 1 |
| Lucas, V | 1 |
| Delwail, V | 1 |
| Thyss, A | 1 |
| Maloisel, F | 1 |
| Milpied, N | 1 |
| le Gouill, S | 1 |
| Lamy, T | 1 |
| Gressin, R | 1 |
| Fabbri, A | 1 |
| Cencini, E | 1 |
| Pietrini, A | 1 |
| Gozzetti, A | 1 |
| Defina, M | 1 |
| Fontanelli, G | 1 |
| Mazzei, MA | 1 |
| Volterrani, L | 1 |
| Bocchia, M | 1 |
| Dong, M | 1 |
| He, XH | 1 |
| Liu, P | 1 |
| Qin, Y | 1 |
| Yang, JL | 1 |
| Zhou, SY | 1 |
| Yang, S | 1 |
| Zhang, CG | 1 |
| Gui, L | 1 |
| Zhou, LQ | 1 |
| Shi, YK | 1 |
| Sato, T | 1 |
| Kogawa, K | 1 |
| Iyama, S | 1 |
| Kobayashi, D | 1 |
| Sato, Y | 1 |
| Kuribayashi, K | 1 |
| Takada, K | 1 |
| Hagiwara, S | 1 |
| Oku, T | 1 |
| Takahashi, S | 1 |
| Matsunaga, T | 1 |
| Takahashi, M | 1 |
| Terui, T | 1 |
| Kato, J | 1 |
| Niitsu, Y | 1 |
| Nomura, E | 1 |
| Isoda, K | 1 |
| Yamanaka, K | 1 |
| Yamaguchi, M | 1 |
| Hakamada, A | 1 |
| Mizutani, H | 1 |
| Mittal, S | 1 |
| Milner, BJ | 1 |
| Johnston, PW | 1 |
| Culligan, DJ | 1 |
| Bishton, MJ | 1 |
| Haynes, AP | 1 |
| Williams, KM | 1 |
| Higman, MA | 1 |
| Chen, AR | 1 |
| Schwartz, CL | 1 |
| Wharam, M | 1 |
| Colombani, P | 1 |
| Arceci, RJ | 1 |
| Kako, S | 1 |
| Izutsu, K | 1 |
| Oshima, K | 1 |
| Sato, H | 1 |
| Kanda, Y | 1 |
| Motokura, T | 1 |
| Chiba, S | 1 |
| Kurokawa, M | 1 |
| Siegert, W | 1 |
| Nerl, C | 1 |
| Engelhard, M | 1 |
| Brittinger, G | 1 |
| Tiemann, M | 1 |
| Parwaresch, R | 1 |
| Heinz, R | 1 |
| Huhn, D | 1 |
| Ciaudo, M | 1 |
| Chauvenet, L | 1 |
| Audouin, J | 1 |
| Rossert, J | 1 |
| Favier, R | 1 |
| Horellou, MH | 1 |
| Bernadou, A | 1 |
| Samama, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma[NCT01590732] | Phase 1 | 22 participants (Actual) | Interventional | 2012-10-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ifosfamide and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Lym | 2022 |
Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carboplatin; Etoposide; Huma | 2022 |
4 trials available for ifosfamide and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance; Etoposide; Humans; Ifo | 2018 |
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclo | 2010 |
Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Celiac Disease; Combined Modality | 2007 |
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1994 |
14 other studies available for ifosfamide and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carboplatin; Depsipeptides; Eto | 2022 |
Systemic Epstein-Barr virus-positive T-cell lymphoma of childhood treated with the ICE regimen and allogeneic hematopoietic stem-cell transplantation.
Topics: Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans | 2023 |
Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carboplatin; Drug | 2021 |
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Co | 2013 |
Treatment of peripheral T cell lymphoma with an intensive protocol ACEP (adriamycin, cyclophosphamide, etoposide and prednisolone) and ifosfamide showing an important response and overall survival rates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fem | 2013 |
Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celiac Disease; Comb | 2010 |
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 2013 |
Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamet | 2013 |
Successful treatment of advanced peripheral T-cell lymphoma with an angiocentric growth pattern complicated with hemophagocytic syndrome by high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Femal | 2002 |
Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Combined Modality | 2005 |
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neop | 2006 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2008 |
Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Crypt | 2007 |
Peripheral-T-cell lymphoma with hemophagocytic histiocytosis localised to the bone marrow associated with inappropriate secretion of antidiuretic hormone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Cy | 1995 |